CytomX wins FDA Fast Track for EpCAM ADC in metastatic colorectal cancer

CytomX Therapeutics has received FDA Fast Track Designation for varsetatug masetecan (Varseta-M) in relapsed/refractory metastatic colorectal cancer, a move the South San Francisco company says paves the way for an accelerated regulatory dialogue as it prepares for a pivotal trial.

Varseta-M is an antibody-drug conjugate directed against epithelial cell adhesion molecule (EpCAM), armed with a topoisomerase-1 inhibitor payload. CytomX describes it as a potential first-in-class agent in this setting, positioning the candidate as the first clinically viable approach to EpCAM, a target long considered attractive but historically undruggable because of its expression on normal tissue as well as tumour cells.

The company's solution to that problem is its PROBODY platform, which applies a masking mechanism to the antibody that is designed to limit activation to the tumour microenvironment. That conditional-activation concept is central to CytomX's broader pipeline, which also includes CX-801, a masked interferon alpha-2b candidate currently in development for metastatic melanoma.

Regulatory path

Fast Track Designation is intended to facilitate the development and expedite review of therapies addressing serious conditions with unmet medical need. It does not constitute approval, nor does it guarantee a particular review timeline, but it does open the door to more frequent FDA interactions and rolling review of the application dossier.

CytomX said the designation followed encouraging Phase 1 data in relapsed/refractory metastatic colorectal cancer that were previously disclosed. The company is planning to initiate a potential registrational monotherapy study in the first half of 2027. No trial design details, primary endpoint, or patient numbers were specified in the announcement.

Sean McCarthy, chairman and chief executive, said Varseta-M was "intentionally designed" for colorectal cancer patients based on EpCAM's high expression profile in the tumour type, calling Fast Track Designation "an important milestone" for the programme.

Market context

Metastatic colorectal cancer is a highly competitive and clinically difficult segment. Approved standards of care in later lines include regorafenib and trifluridine/tipiracil, both of which offer modest survival benefit, and the VEGFR-2 antibody ramucirumab in combination. ADC activity in colorectal cancer has historically been limited compared with breast and lung cancer, partly because of the challenge of identifying tumour-selective targets. EpCAM's broad expression profile has previously frustrated several targeting attempts, which is why CytomX's masking approach draws interest if the Phase 1 signal proves durable.

Varseta-M was originally discovered in collaboration with ImmunoGen, now part of AbbVie, a partnership that gives the programme a pedigree in ADC linker-payload chemistry. CytomX also holds collaborations with Amgen, Regeneron and Moderna across its wider pipeline, providing financial and scientific support as it moves toward the pivotal readout window.

The key near-term catalyst is the Phase 1 data package that CytomX has signalled but not yet published in full. Investors and oncologists will be looking for confirmed response rates, duration of response, and the safety profile of the topoisomerase-1 payload in this patient population before forming a view on registrational prospects.